In 12,327 patients with noncardioembolic ischaemic stroke or high-risk TIA on antiplatelet therapy, asundexian 50 mg daily cut ischaemic stroke vs placebo (6.2% vs 8.4%; HR 0.74) without more major bleeding (1.9% vs 1.7%).
RCTn = 12,327
Sharma et al. Asundexian for Secondary Stroke Prevention